- Active not recruitingPHASE1
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
This study is testing a new medicine called tarlatamab for adults with small cell lung cancer. It aims to see how safe it is, how well people tolerate it, and how it moves through the body.
For: Small Cell Lung CarcinomaUnited States · Australia · Austria - Active not recruitingPHASE2
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
This study is testing a new medicine called tarlatamab for people with a type of lung cancer called Small Cell Lung Cancer (SCLC) that has come back or not responded to previous treatments. It aims to see how safe and effective the new medicine is.
For: Relapsed/Refractory Small Cell Lung CancerUnited States · Austria · Belgium - Active not recruitingPHASE3
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
This study is looking at a new treatment called Tarlatamab for advanced small cell lung cancer that has come back after earlier treatment. We want to see if Tarlatamab helps people live longer compared to standard chemotherapy.
For: Small Cell Lung Cancer (SCLC)United States · Argentina · Australia - RecruitingPHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
This study is testing a new drug, Ris-Rez, for people with advanced cancers. Researchers want to see if it's safe, how it works, and if it can help stop cancer growth, both alone and with other medicines.
For: NeoplasmsUnited States · Argentina · Canada - Active not recruitingPHASE2
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
This study is looking into a new treatment called tarlatamab for small cell lung cancer (SCLC). It aims to see how well it works and how safe it is for people whose cancer has progressed after other treatments.
For: Small Cell Lung Cancer (SCLC)United States · Argentina · Australia - Active not recruitingPHASE3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
This study looks at a new drug, Tarlatamab, for people with a type of lung cancer called limited-stage small-cell lung cancer (LS-SCLC). It aims to see if Tarlatamab can help people live longer without their cancer getting worse after chemotherapy and radiotherapy.
For: Limited Stage Small Cell Lung Cancer · Small Cell Lung CancerUnited States · Argentina · Australia